COMPANY:

Quantgene

"Startup Quantgene is attempting to break into the early cancer detection market with a liquid biopsy sequencing service called Serenity that it currently markets directly to consumers with physician signoff and claims can provide a risk assessment for seven different cancer types...Quantgene has raised roughly $20 million in seed funding, Series A financing, and through a recent partnership with Charleston, South Carolina-based molecular diagnostic company Vikor Scientific...While Quantgene designed the DeepGen assay to detect variants 'associated with 15 cancer types,'...the Serenity service identifies markers linked to seven cancers, including pancreatic, breast, colorectal, liver, bladder, lung, and prostate cancer. He added that the firm plans to improve the solution to detect all 15 cancers by mid-2022."